MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Up 0.3% – Should You Buy?

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares were up 0.3% during trading on Tuesday . The stock traded as high as $0.97 and last traded at $0.9540. Approximately 20,712 shares traded hands during trading, a decline of 85% from the average session volume of 134,455 shares. The stock had previously closed at $0.9515.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a report on Friday, March 27th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold”.

MIRA Pharmaceuticals Trading Down 0.3%

The stock’s fifty day simple moving average is $1.01 and its 200 day simple moving average is $1.19. The company has a market cap of $38.14 million, a price-to-earnings ratio of -0.70 and a beta of 1.43.

MIRA Pharmaceuticals (NASDAQ:MIRA) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.03) earnings per share (EPS) for the quarter.

Institutional Trading of MIRA Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new position in shares of MIRA Pharmaceuticals during the 2nd quarter valued at about $26,000. Creative Planning acquired a new stake in MIRA Pharmaceuticals during the second quarter worth about $27,000. Fifth Third Bancorp purchased a new position in MIRA Pharmaceuticals during the fourth quarter worth about $30,000. Two Sigma Investments LP raised its stake in MIRA Pharmaceuticals by 129.8% during the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock worth $62,000 after purchasing an additional 25,816 shares during the period. Finally, First American Bank boosted its holdings in MIRA Pharmaceuticals by 20.0% in the 4th quarter. First American Bank now owns 60,000 shares of the company’s stock valued at $91,000 after purchasing an additional 10,000 shares during the last quarter. 35.16% of the stock is owned by institutional investors and hedge funds.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.